BioImagene Announces Board Expansion and Appoints Biotechnology Veteran G Steven Burrill as Chairman
Cupertino, CA, Aug 27, 2008
BioImagene, the
leading provider of innovative and affordable digital pathology
solutions for cancer diagnosis and pre clinical research,
today announced the appointment of G
Steven Burrill as chairman of the board.
The company also announced the appointment of two new board
members. The new members include Mr.
Taras Silecky of Ascension Health Ventures and Dr.
Ajit Singh, CEO of the Image and Knowledge Management
business of Siemens Healthcare who will join as an independent
board member.
These announcements come at the heels of the recent closing
of a $26 million series D financing round led by Burrill & Company, Ascension
Health Ventures, National
Healthcare Services as well as existing investors Artiman
Ventures and ICCP
Ventures
Mr. Steven Burrill said “We are delighted to join
a distinguished group of investors and an experienced management
team. Digital pathology, riding on the convergence of innovations
in biomarker discovery, pathology and imaging technology
is primed for personalized medicine supporting our Healthcare
Vision 2020.”
”We are fortunate to have the insight and experience
of Mr. Burrill, Dr. Singh and Mr. Silecky” said Mohan
Uttarwar CEO, BioImagene. Mr. Uttarwar continued, “Their
addition, along with our world class management team and
the infusion of capital will enable BioImagene extend its
dominant position in technology innovation and business models.
We are now prepared for a full scale operation.”
Dr Ajit Singh said,” Pathology is poised for the widespread
adoption of technology just as radiology was, ten years ago.
Technology focused companies using digital pathology applications
will experience the inherent value of greater efficiency,
productivity and standardization in pathology workflows.
More importantly, there are some innovations that are possible only in
the digital world, such as use of knowledge-based algorithms,
data mining, and decision support.”
“Hospitals are entering the digital age and digital pathology is a major
step towards an integrated workflow and EMR. It enables a quick and efficient
exchange of information ultimately improving the speed and quality of patient
care with greater levels of accuracy,” commented Mr. Taras Silecky.
About BioImagene
BioImagene is a leading provider of total digital pathology
solutions for applications including clinical diagnostics
and drug discovery. BioImagene products are FDA -cleared
for specific clinical applications, and are intended for
research use for other applications. www.bioimagene.com.
Media contact: Suchi Parth 408 207 4285
|
